Home > Publications Database > Subthalamic nucleus deep brain stimulation induces functional deficits in norepinephrinergic neurotransmission in a Parkinson’s disease model > print

001     271077
005     20250127091652.0
024 7 _ |a pmid:39053685
|2 pmid
024 7 _ |a 10.1016/j.brainres.2024.149128
|2 doi
024 7 _ |a 0006-8993
|2 ISSN
024 7 _ |a 1872-6240
|2 ISSN
037 _ _ |a DZNE-2024-00949
082 _ _ |a 610
100 1 _ |a Statz, Meike
|b 0
245 _ _ |a Subthalamic nucleus deep brain stimulation induces functional deficits in norepinephrinergic neurotransmission in a Parkinson’s disease model
260 _ _ |a Amsterdam
|c 2024
|b Elsevier
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1723110613_2212
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Deep brain stimulation of the subthalamic nucleus (STN-DBS) is a successful treatment option in Parkinson's disease (PD) for different motor and non-motor symptoms, but has been linked to postoperative cognitive impairment.Since both dopaminergic and norepinephrinergic neurotransmissions play important roles in symptom development, we analysed STN-DBS effects on dopamine and norepinephrine availability in different brain regions and morphological alterations of catecholaminergic neurons in the 6-hydroxydopamine PD rat model.We applied one week of continuous unilateral STN-DBS or sham stimulation, respectively, in groups of healthy and 6-hydroxydopamine-lesioned rats to quantify dopamine and norepinephrine contents in the striatum, olfactory bulb and dentate gyrus. In addition, we analysed dopaminergic cell counts in the substantia nigra pars compacta and area tegmentalis ventralis and norepinephrinergic neurons in the locus coeruleus after one and six weeks of STN-DBS.In 6-hydroxydopamine-lesioned animals, one week of STN-DBS did not alter dopamine levels, while striatal norepinephrine levels were decreased. However, neither one nor six weeks of STN-DBS altered dopaminergic neuron numbers in the midbrain or norepinephrinergic neuron counts in the locus coeruleus. Dopaminergic fibre density in the dorsal and ventral striatum also remained unchanged after six weeks of STN-DBS. In healthy animals, one week of STN-DBS resulted in increased dopamine levels in the olfactory bulb and decreased contents in the dentate gyrus, but had no effects on norepinephrine availability.STN-DBS modulates striatal norepinephrinergic neurotransmission in a PD rat model. Additional behavioural studies are required to investigate the functional impact of this finding.
536 _ _ |a 353 - Clinical and Health Care Research (POF4-353)
|0 G:(DE-HGF)POF4-353
|c POF4-353
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, Journals: pub.dzne.de
650 _ 2 |a Animals
|2 MeSH
650 _ 2 |a Subthalamic Nucleus: metabolism
|2 MeSH
650 _ 2 |a Deep Brain Stimulation: methods
|2 MeSH
650 _ 2 |a Male
|2 MeSH
650 _ 2 |a Oxidopamine: toxicity
|2 MeSH
650 _ 2 |a Synaptic Transmission: physiology
|2 MeSH
650 _ 2 |a Dopamine: metabolism
|2 MeSH
650 _ 2 |a Disease Models, Animal
|2 MeSH
650 _ 2 |a Norepinephrine: metabolism
|2 MeSH
650 _ 2 |a Rats
|2 MeSH
650 _ 2 |a Parkinson Disease: metabolism
|2 MeSH
650 _ 2 |a Parkinson Disease: therapy
|2 MeSH
650 _ 2 |a Dopaminergic Neurons: metabolism
|2 MeSH
650 _ 2 |a Olfactory Bulb: metabolism
|2 MeSH
650 _ 2 |a Rats, Sprague-Dawley
|2 MeSH
650 _ 2 |a Corpus Striatum: metabolism
|2 MeSH
650 _ 2 |a Dentate Gyrus: metabolism
|2 MeSH
650 _ 2 |a Parkinsonian Disorders: metabolism
|2 MeSH
650 _ 2 |a Parkinsonian Disorders: therapy
|2 MeSH
650 _ 2 |a Parkinsonian Disorders: physiopathology
|2 MeSH
700 1 _ |a Weber, Hanna
|b 1
700 1 _ |a Weis, Frederike
|b 2
700 1 _ |a Kober, Maria
|b 3
700 1 _ |a Bathel, Henning
|b 4
700 1 _ |a Plocksties, Franz
|b 5
700 1 _ |a van Rienen, Ursula
|b 6
700 1 _ |a Timmermann, Dirk
|b 7
700 1 _ |a Storch, Alexander
|0 P:(DE-2719)9000306
|b 8
|u dzne
700 1 _ |a Fauser, Mareike
|b 9
773 _ _ |a 10.1016/j.brainres.2024.149128
|g Vol. 1841, p. 149128 -
|0 PERI:(DE-600)1462674-3
|p 149128
|t Brain research
|v 1841
|y 2024
|x 0006-8993
856 4 _ |u https://pub.dzne.de/record/271077/files/DZNE-2024-00949%20SUP.docx
856 4 _ |y OpenAccess
|u https://pub.dzne.de/record/271077/files/DZNE-2024-00949.pdf
856 4 _ |u https://pub.dzne.de/record/271077/files/DZNE-2024-00949%20SUP.doc
856 4 _ |u https://pub.dzne.de/record/271077/files/DZNE-2024-00949%20SUP.odt
856 4 _ |u https://pub.dzne.de/record/271077/files/DZNE-2024-00949%20SUP.pdf
856 4 _ |y OpenAccess
|x pdfa
|u https://pub.dzne.de/record/271077/files/DZNE-2024-00949.pdf?subformat=pdfa
909 C O |o oai:pub.dzne.de:271077
|p openaire
|p open_access
|p VDB
|p driver
|p dnbdelivery
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 8
|6 P:(DE-2719)9000306
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-353
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Clinical and Health Care Research
|x 0
914 1 _ |y 2024
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2023-08-28
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2023-08-28
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2023-08-28
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2023-08-28
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2023-08-28
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b BRAIN RES : 2022
|d 2023-08-28
915 _ _ |a Creative Commons Attribution-NonCommercial CC BY-NC 4.0
|0 LIC:(DE-HGF)CCBYNC4
|2 HGFVOC
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2023-08-28
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
|d 2023-08-28
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2023-08-28
915 _ _ |a IF < 5
|0 StatID:(DE-HGF)9900
|2 StatID
|d 2023-08-28
915 _ _ |a OpenAccess
|0 StatID:(DE-HGF)0510
|2 StatID
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2023-08-28
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2023-08-28
915 _ _ |a Nationallizenz
|0 StatID:(DE-HGF)0420
|2 StatID
|d 2023-08-28
|w ger
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2023-08-28
920 1 _ |0 I:(DE-2719)5000014
|k AG Storch
|l Non-Motor Symptoms in Parkinson's disease
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a UNRESTRICTED
980 _ _ |a I:(DE-2719)5000014
980 1 _ |a FullTexts

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21